Blue Water Vaccines Announces Plans to Evaluate Efficacy of Streptococcus pneumoniae Vaccine Candidate Against Pneumococcal Pneumonia at the World Vaccine Congress in Barcelona
October 11, 2022 09:15 ET
|
Blue Water Vaccines Inc.
CINCINNATI, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address...
Blue Water Vaccines to Present at World Vaccine Congress Europe 2022
September 21, 2022 08:00 ET
|
Blue Water Vaccines Inc.
CINCINNATI, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address...
Blue Water Vaccines to Present In Person and via Webcast at H.C. Wainwright’s 24th Annual Global Investment Conference in New York, NY
September 08, 2022 10:30 ET
|
Blue Water Vaccines Inc.
CINCINNATI, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing transformational vaccines to address...
Blue Water Vaccines to Present at H.C. Wainwright’s 24th Annual Global Investment Conference in New York, NY
August 31, 2022 08:30 ET
|
Blue Water Vaccines Inc.
CINCINNATI, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing transformational vaccines to address...
Blue Water Vaccines to Present at The Universal Influenza Vaccines 2022 Conference in Oxford, United Kingdom
August 24, 2022 14:00 ET
|
Blue Water Vaccines Inc.
CINCINNATI, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing transformational vaccines to address...
Blue Water Vaccines Announces Appointment of Retired Deloitte Consulting Senior Managing Director Simon Tarsh to Board of Directors
August 22, 2022 14:00 ET
|
Blue Water Vaccines Inc.
CINCINNATI, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines to address...
Blue Water Vaccines Announces Exploration of Its Virus-Like Particle (VLP) Platform for Use in Monkeypox Vaccine Candidate
August 17, 2022 08:30 ET
|
Blue Water Vaccines Inc.
CINCINNATI, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines to address...
Blue Water Vaccines Reports Second Quarter 2022 Financial Results and Recent Business Highlights
August 15, 2022 16:00 ET
|
Blue Water Vaccines Inc.
Closed private placement in April 2022, with net proceeds of approximately $6.9 millionSigned multiple strategic agreements and collaborations to further vaccine candidate research, development, and...
Blue Water Vaccines Announces Closing of $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules
August 11, 2022 13:47 ET
|
Blue Water Vaccines Inc.
CINCINNATI, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address...
Blue Water Vaccines Announces $10 Million Private Placement Priced At-the-Market under Nasdaq Rules
August 09, 2022 08:00 ET
|
Blue Water Vaccines Inc.
CINCINNATI, Ohio, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines to...